A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants

Study identifier:ACE-HV-009

ClinicalTrials.gov identifier:NCT04898101

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Absolute Bioavailability, Pharmacokinetics, Excretion, and Metabolism of [14C]Acp-196 (Acalabrutinib) in Healthy Subjects

Medical condition

Healthy Volunteers

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Acalabrutinib, Microtracer [14C]ACP-196

Sex

All

Actual Enrollment

14

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 03 Mar 2016
Primary Completion Date: 13 Apr 2016
Study Completion Date: 13 Apr 2016

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2021 by Acerta Pharma BV

Sponsors

Acerta Pharma BV

Collaborators

-

Inclusion and exclusion criteria